PAG
PACB icon

Private Advisor Group’s Pacific Biosciences PACB Stock Holding History

Private Advisor Group’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$29K Sell
17,237
-7,500
-30% -$10.9K ﹤0.01% 2485
2026
Q1 		$32.7K Buy
24,737
+441
+2% +$789 ﹤0.01% 2602
2025
Q4 		$45.4K Sell
24,296
-4,323
-15% -$8.31K ﹤0.01% 2524
2025
Q3 		$36.6K Sell
28,619
-1,150
-4% -$1.56K ﹤0.01% 2468
2025
Q2 		$36.9K Buy
29,769
+6,386
+27% +$7.38K ﹤0.01% 2366
2025
Q1 		$27.6K Sell
23,383
-2,625
-10% -$4.03K ﹤0.01% 2261
2024
Q4 		$47.6K Sell
26,008
-1,853
-7% -$3.62K ﹤0.01% 2215
2024
Q3 		$47.4K Buy
27,861
+143
+0.5% +$235 ﹤0.01% 2353
2024
Q2 		$38K Buy
27,718
+2,385
+9% +$4.82K ﹤0.01% 2283
2024
Q1 		$95K Buy
25,333
+5,942
+31% +$34.8K ﹤0.01% 2204
2023
Q4 		$190K Sell
19,391
-349
-2% -$2.85K ﹤0.01% 2052
2023
Q3 		$165K Buy
19,740
+2,027
+11% +$23.2K ﹤0.01% 1912
2023
Q2 		$236K Buy
17,713
+4,402
+33% +$53.5K ﹤0.01% 1770
2023
Q1 		$154K Buy
13,311
+500
+4% +$4.97K ﹤0.01% 1826
2022
Q4 		$105 Sell
12,811
-900
-7% -$7.75K ﹤0.01% 1578
2022
Q3 		$80K Sell
13,711
-1,458
-10% -$8.37K ﹤0.01% 1801
2022
Q2 		$67K Sell
15,169
-4,377
-22% -$26.6K ﹤0.01% 1990
2022
Q1 		$178K Buy
19,546
+59
+0.3% +$679 ﹤0.01% 1918
2021
Q4 		$399K Buy
19,487
+3,300
+20% +$79.6K ﹤0.01% 1577
2021
Q3 		$414K Sell
16,187
-400
-2% -$11.9K ﹤0.01% 1596
2021
Q2 		$580K Sell
16,587
-851
-5% -$24.8K 0.01% 1319
2021
Q1 		$581K Buy
17,438
+2,552
+17% +$89.3K 0.01% 1230
2020
Q4 		$386K Buy
14,886
+566
+4% +$9.62K ﹤0.01% 1346
2020
Q3 		$141K Buy
14,320
+7,755
+118% +$44.6K ﹤0.01% 1457
2020
Q2 		$23K Buy
+6,565
New +$22.4K ﹤0.01% 2502
2019
Q4 		– Sell
-10,000
Closed -$52K – 1713
2019
Q3 		$52K Buy
+10,000
New +$55.9K ﹤0.01% 1604

Other funds holding PACB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Private Advisor Group's PACB Position: Q2 2026 in Review

Private Advisor Group reduced its Pacific Biosciences (PACB) stake by 30% in Q2 2026, selling an estimated $10.9K and leaving 17,237 shares worth $29K. The position accounts for ﹤0.01% of the portfolio, ranked #2485.

Private Advisor Group first reported a position in PACB in Q3 2019 and has held it in 26 quarters since. The position peaked at $581K in Q1 2021. 223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

  • Private Advisor Group held 17,237 shares of Pacific Biosciences worth $29K as of Q2 2026.
  • Private Advisor Group sold 7,500 Pacific Biosciences shares in Q2 2026, an estimated $10.9K.
  • Pacific Biosciences made up ﹤0.01% of Private Advisor Group's portfolio in Q2 2026, its #2485 holding.
  • Private Advisor Group first reported a position in Pacific Biosciences in Q3 2019 and has held it in 26 quarters since.
  • Private Advisor Group's Pacific Biosciences position peaked at $581K in Q1 2021.
  • 223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on Private Advisor Group's 13F filing for Q2 2026, filed 27 Jul 2026.